New immune combo tackles Hard-to-Treat colorectal cancer
Disease control
Recruiting now
This early-phase trial tests a combination of three treatments for advanced colorectal cancer that has not responded to standard therapies. The approach uses the patient's own immune cells (DC-CIK), a targeted drug (regorafenib), and a bispecific antibody to boost the immune syst…
Phase: EARLY_PHASE1 • Sponsor: JIANG LONGWEI • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC